Compare mobile phone specifications of up to three devices at once. Our specs comparison tool helps you find and compare the perfect phone for your needs.

Y37.08 bln Per share Earnings (Y95.74) Y169.27 Figures in parentheses are losses. Results are based on Japanese accounting standards. This content was automatically published based on data and/or ...

GlobalAir.com receives its data from NOAA, NWS, FAA and NACO, and Weather Underground. We strive to maintain current and accurate data. However, GlobalAir.com cannot guarantee the data received from ...

Vivo's next foldable smartphone will reportedly be named the Vivo X Fold 5, skipping Vivo X Fold 4. It is tipped to feature an 8.03-inch internal screen and a 6.53-inch cover display. It is said to ...

The vivo Y300 series just got its latest member with the Y300 GT. The device was announced in China and features similar specs to the recently announced iQOO Z10 Turbo. Y300 GT features a 6.78 ...

Vivo has officially debuted as a new addition to the Y300 series, which already include models, such as Y300, Y300+, Y300i, Y300t, and Y300 Pro+. The major attractions of the Y300 GT include a ...

vivo has introduced the vivo Y300 GT smartphone in China, which has similar specifications as the iQOO Z10 Turbo, which was introduced last week. To remind you, this packs a 6.78-inch 1.5K 144FPS ...

Nagoya Railroad Co. Ltd. (9048.TO) Japan Year Ended March 31 GROUP 2025 2024 Revenue Y690.72 bln Y601.12 bln Operating Profit Y42.08 bln Y34.75 bln Pretax Profit Y47.67 bln Y37.54 bln Net Profit ...

Recent reports have revealed that Vivo is preparing to launch a mini phone under its S-series lineup in China. While the official moniker of the device is not known yet, it is likely to be called ...

California investment firm Vivo Capital has secured $740 million in commitments to be aimed at preclinical- and clinical-stage life sciences companies. The Vivo Opportunity Fund is an evergreen ...

CRISPR Therapeutics has reported reductions in triglycerides and LDL cholesterol of more than 80% after a single dose of its in vivo liver editing prospect CTX310, encouraging the company to forge ...